跳至主要内容
临床试验/CTRI/2017/10/009959
CTRI/2017/10/009959招募中未知

Development of a mathematical model to predict the occurrence of recurrent grade 2 or grade 3 Hand Foot Skin Reaction requiring dose modification in patients with either metastatic Renal Cell Carcinoma or unresectable Hepato Cellular Carcinoma receiving standard dose of Sorafenib.

Terry Fox Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patients age > 18 yrs
  • 1.Gender: male/female
  • 2.Patients with Metastatic Renal cell carcinoma
  • or Advanced Hepatocellular Carcinoma.
  • 3. Patients who are sorafenib naive or those
  • who are already on sorafenib without
  • recurrent grade 2 or grade 3 HFSR over a
  • period of 8 weeks or more on standard dose of sorafenib.
  • 4. ECOG status 0 to 2.
  • 5. Patients who are capable of providing written informed consent form

排除标准

  • 1. Patients simultaneously taking another anti-
  • cancer agent or combination of anti-cancer agents known to cause hand foot syndrome
  • 2.Patients with pre-existing dermatological
  • condition affecting the hands or feet
  • 3.Patients with an active dermatological
  • condition due to previous chemotherapy or
  • biologic therapy affecting the hands

研究者

发起方
Terry Fox Tata Memorial Centre

相似试验